As of 2026-04-06, the Relative Valuation of Arcus Biosciences Inc (RCUS) is (61.04) USD. This relative valuation is based on P/E multiples. With the latest stock price at 22.24 USD, the upside of Arcus Biosciences Inc based on Relative Valuation is -374.5%.
The range of the Relative Valuation is (58.07) - (63.64) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.9x - 24.7x | 22.2x |
| Forward P/E multiples | 20.6x - 22.6x | 21.2x |
| Fair Price | (58.07) - (63.64) | (61.04) |
| Upside | -361.1% - -386.2% | -374.5% |
| Date | P/E |
| 2026-04-06 | -7.90 |
| 2026-04-02 | -8.15 |
| 2026-04-01 | -7.76 |
| 2026-03-31 | -7.67 |
| 2026-03-30 | -7.33 |
| 2026-03-27 | -7.20 |
| 2026-03-26 | -7.53 |
| 2026-03-25 | -7.62 |
| 2026-03-24 | -7.19 |
| 2026-03-23 | -7.60 |
| 2026-03-20 | -7.68 |
| 2026-03-19 | -7.96 |
| 2026-03-18 | -7.89 |
| 2026-03-17 | -8.02 |
| 2026-03-16 | -7.97 |
| 2026-03-13 | -7.80 |
| 2026-03-12 | -8.06 |
| 2026-03-11 | -8.67 |
| 2026-03-10 | -8.72 |
| 2026-03-09 | -8.32 |
| 2026-03-06 | -7.85 |
| 2026-03-05 | -7.89 |
| 2026-03-04 | -8.05 |
| 2026-03-03 | -7.96 |
| 2026-03-02 | -8.50 |
| 2026-02-27 | -7.23 |
| 2026-02-26 | -6.94 |
| 2026-02-25 | -7.20 |
| 2026-02-24 | -7.17 |
| 2026-02-23 | -6.69 |
| 2026-02-20 | -6.74 |
| 2026-02-19 | -6.92 |
| 2026-02-18 | -6.90 |
| 2026-02-17 | -6.83 |
| 2026-02-13 | -6.72 |
| 2026-02-12 | -7.09 |
| 2026-02-11 | -7.58 |
| 2026-02-10 | -7.38 |
| 2026-02-09 | -7.50 |
| 2026-02-06 | -7.47 |
| 2026-02-05 | -7.11 |
| 2026-02-04 | -7.45 |
| 2026-02-03 | -7.80 |
| 2026-02-02 | -7.69 |
| 2026-01-30 | -7.47 |
| 2026-01-29 | -7.74 |
| 2026-01-28 | -7.71 |
| 2026-01-27 | -8.16 |
| 2026-01-26 | -7.98 |
| 2026-01-23 | -7.86 |